Biogen ALS Drug Showed No Benefit, O'Neill Says

Jan. 3 (Bloomberg) -- Gilmore O’Neill, vice president of clinical development at Biogen Idec Inc., talks with Bloomberg's Meg Tirrell about the company's announcement that its experimental drug for amyotrophic lateral sclerosis failed to help patients in a clinical trial. Biogen sank 1.4 percent to $147.86 at 4 p.m. New York time after saying it will end development of the medicine for ALS, also known as Lou Gehrig’s disease. (Source: Bloomberg)
Will the Nasdaq Maintain its Momentum?
38:17 - March 3 -- Westwood Capital’s Lincoln Ellis and Bloomberg Contributing Editor Paul Kedrosky discuss the performance of the Nasdaq. They speaks on “Bloomberg West.”
  • Why PayPal Is Buying Mobile-Payment Startup Paydiant
  • Zetsche: Autos to See Next Stage of Battery Technology
  • Netanyahu's Address to Congress in Two Minutes